This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Davis-Searles, P. R. Articles by Kroll, D. J. Search for Related Content PubMed PubMed Citation Articles by Davis-Searles, P. R. Articles by Kroll, D. J.

Milk Thistle and Prostate Cancer: Differential Effects of Pure Flavonolignans from Silybum marianum on Antiproliferative End Points in Human Prostate Carcinoma Cells

¹ Natural Products Laboratory, Research Triangle Institute, Research Triangle Park, North Carolina and ² Department of Pharmaceutical Sciences, School of Pharmacy, University of Colorado Health Sciences Center, Denver, Colorado

Requests for reprints: David J. Kroll, Natural Products Laboratory, Center for Organic and Medicinal Chemistry, Research Triangle Institute International, 3040 Cornwallis Road, Box 12194, Research Triangle Park, NC 27709-2194. Phone: 919-485-2605; Fax: 919-541-8868; E-mail: kroll{at}rti.org.

Extracts from the seeds of milk thistle, Silybum marianum, are known commonly as silibinin and silymarin and possess anticancer actions on human prostate carcinoma in vitro and in vivo. Seven distinct flavonolignan compounds and a flavonoid have been isolated from commercial silymarin extracts. Most notably, two pairs of diastereomers, silybin A and silybin B and isosilybin A and isosilybin B, are among these compounds. In contrast, silibinin is composed only of a 1:1 mixture of silybin A and silybin B. With these isomers now isolated in quantities sufficient for biological studies, each pure compound was assessed for antiproliferative activities against LNCaP, DU145, and PC3 human prostate carcinoma cell lines. Isosilybin B was the most consistently potent suppressor of cell growth relative to either the other pure constituents or the commercial extracts. Isosilybin A and isosilybin B were also the most effective suppressors of prostate-specific antigen secretion by androgen-dependent LNCaP cells. Silymarin and silibinin were shown for the first time to suppress the activity of the DNA topoisomerase II gene promoter in DU145 cells and, among the pure compounds, isosilybin B was again the most effective. These findings are significant in that isosilybin B composes no more than 5% of silymarin and is absent from silibinin. Whereas several other more abundant flavonolignans do ultimately influence the same end points at higher exposure concentrations, these findings are suggestive that extracts enriched for isosilybin B, or isosilybin B alone, might possess improved potency in prostate cancer prevention and treatment.

This article has been cited by other articles:

				A. Tyagi, K. Raina, R. P. Singh, M. Gu, C. Agarwal, G. Harrison, L. M. Glode, and R. Agarwal Chemopreventive effects of silymarin and silibinin on N-butyl-N-(4-hydroxybutyl) nitrosamine induced urinary bladder carcinogenesis in male ICR mice Mol. Cancer Ther., December 1, 2007; 6(12): 3248 - 3255. [Abstract] [Full Text] [PDF]

				L. Reddivari, J. Vanamala, S. Chintharlapalli, S. H. Safe, and J.C. Miller Jr Anthocyanin fraction from potato extracts is cytotoxic to prostate cancer cells through activation of caspase-dependent and caspase-independent pathways Carcinogenesis, October 1, 2007; 28(10): 2227 - 2235. [Abstract] [Full Text] [PDF]

				G. Deep, N. H. Oberlies, D. J. Kroll, and R. Agarwal Isosilybin B and isosilybin A inhibit growth, induce G1 arrest and cause apoptosis in human prostate cancer LNCaP and 22Rv1 cells Carcinogenesis, July 1, 2007; 28(7): 1533 - 1542. [Abstract] [Full Text] [PDF]

				D. J. Kroll, H. S. Shaw, and N. H. Oberlies Milk Thistle Nomenclature: Why It Matters in Cancer Research and Pharmacokinetic Studies Integr Cancer Ther, June 1, 2007; 6(2): 110 - 119. [Abstract] [PDF]

				M. C. Comelli, U. Mengs, C. Schneider, and M. Prosdocimi Toward the Definition of the Mechanism of Action of Silymarin: Activities Related to Cellular Protection From Toxic Damage Induced by Chemotherapy Integr Cancer Ther, June 1, 2007; 6(2): 120 - 129. [Abstract] [PDF]

				G. Deep and R. Agarwal Chemopreventive Efficacy of Silymarin in Skin and Prostate Cancer Integr Cancer Ther, June 1, 2007; 6(2): 130 - 145. [Abstract] [PDF]

				S. M. Sagar Future Directions for Research on Silybum marianum for Cancer Patients Integr Cancer Ther, June 1, 2007; 6(2): 166 - 173. [Abstract] [PDF]

				B. Malewicz, Z. Wang, C. Jiang, J. Guo, M. P. Cleary, J. P. Grande, and J. Lu Enhancement of mammary carcinogenesis in two rodent models by silymarin dietary supplements Carcinogenesis, September 1, 2006; 27(9): 1739 - 1747. [Abstract] [Full Text] [PDF]